Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 200-664-3 | CAS number: 67-68-5
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Basic toxicokinetics
Administrative data
- Endpoint:
- basic toxicokinetics in vivo
- Type of information:
- migrated information: read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- weight of evidence
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Study well documented, meets generally accepted scientific principles, acceptable for assessment
Data source
Reference
- Reference Type:
- publication
- Title:
- Pharmacokinetics and distribution of [35S]methylsulfonylmethane following oral administration to rats
- Author:
- Magnuson BA, Appleton J and Ames GB
- Year:
- 2 007
- Bibliographic source:
- J Agric Food Chem., 55(3):1033-8
Materials and methods
- Objective of study:
- distribution
- excretion
- toxicokinetics
- Principles of method if other than guideline:
- Investigation of the pharmacokinetics, distribution, and excretion of [35S]MSM in rats
Test material
- Reference substance name:
- Dimethyl sulphone
- EC Number:
- 200-665-9
- EC Name:
- Dimethyl sulphone
- Cas Number:
- 67-71-0
- Molecular formula:
- C2H6O2S
- IUPAC Name:
- dimethyl sulfone
- Reference substance name:
- Methylsulfonylmethane
- IUPAC Name:
- Methylsulfonylmethane
- Details on test material:
- The Methylsulfonylmethane (MSM) used in this study was OptiMSM distilled microprill provided by Cardinal Nutrition, Inc. (Vancouver, WA). Labeled [35S]MSM was prepared by Perkin-Elmer Life Sciences (Boston, MA) as an aqueous solution (5 mCi/mL, 500 mCi/mmol).
Constituent 1
Constituent 2
- Radiolabelling:
- yes
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Taconic Farms (Germantown, NY)
- Age at reception: 7-8 weeks old
- Fasting period before study: overnight and for approximately 4 h postdose
- Housing:
- Diet: Harlan Teklad Certified Rodent Diet 8728C, ad libitum
- Water: ad libitum
- Acclimation period: >1 week
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- water
- Duration and frequency of treatment / exposure:
- Single
Doses / concentrations
- Remarks:
- Doses / Concentrations:
500 mg/kg and 50 µCi/rat
- Details on dosing and sampling:
- Five rats were designated group 1 (blood group), and three rats were designated group 2 (urine and feces group). Samples of blood were collected at 0, 15, and 30 min and 1, 2, 4, 8, 12, 24, and 48 h from group 1. Tissues were collected from group 1 and 2 animals after 48 and 120 h, respectively. Urine and feces were collected during the following time intervals: -24 to 0 (prestudy initiation), 0-24, 24-48, 48-72, 72-96, and 96-120 h after dosing.
PHARMACOKINETIC STUDY (Absorption, distribution, excretion)
- Tissues and body fluids sampled: urine, feces, blood, liver, heart, kidneys, spleen, brain, testes, eyes, scapular skin (shaved), and knee joints (bone and cartilage)s, cage washes
- Time and frequency of sampling: see Table 1
METABOLITE CHARACTERISATION STUDIES
- Tissues and body fluids sampled: as above
- Time and frequency of sampling: see Table 1
- From how many animals: see Table 1
- Method type(s) for identification: Liquid scintillation counting
- Limits of detection and quantification: no data
TREATMENT FOR CLEAVAGE OF CONJUGATES (if applicable): - Statistics:
- Mean and standard deviation calculations were performed using Excel Office XP (Microsoft, Redmond, WA). Pharmacokinetic analysis of the total
35S blood concentration-time data was calculated by noncompartmental analyses using WinNonlin, version 4.1. (Pharsight Corp., Mountain View, CA).
Results and discussion
Main ADME resultsopen allclose all
- Type:
- excretion
- Results:
- Urine (0-120h): 85.8 ± 4.8 % of the dose
- Type:
- excretion
- Results:
- Feces (0-120h): 3.0 ± 3.0 %
- Type:
- excretion
- Results:
- Total (0-120h): 88.9 ± 5.1 %
Toxicokinetic / pharmacokinetic studies
- Details on distribution in tissues:
- Blood Concentrations of MSM.
Oral administration of [35S]-MSM to rats resulted in the rapid appearance of substantial blood concentrations of 35S at the first time point of 15 min postdose and quantifiable concentrations at all time points up to 48 h (Figure 1). Radiolabel concentrations remained close to peak levels for 8 h following dose administration (mean blood levels were >80% of the maximal concentration level from 0.5 to 8 h postdose). The peak mean blood concentration of 618 µg equiv/mL was achieved at 2 h following MSM administration. Significant blood concentrations of radioactivity (>70 times the quantifiable level of 0.816 µg equiv/mL) persisted through the 48 h time point. Examination of the blood
concentrations versus time analysis from individual rats revealed that the blood concentration profile was very consistent from rat to rat (data not shown).
Distribution of Radioactivity.
Total radioactivity appeared to be widely distributed throughout the body, and measurable levels of total 35S were found in all tissues analyzed at 48 h postdose (Table 3).
The highest levels of radiolabel were found in kidney, testes, and eye. These values were comparable ((15%) to the blood concentration (63.7 µg equiv/g) found at the 48 h time point. Radioactivity levels in the skin (51.8 µg equiv/g) and bone (35.2 µg equiv/g) were lower than the (15% range. No quantifiable levels of radioactivity (values greater than twice ranging from 0.76 to 2.43 µg equiv/g depending on the tissue) were found in any of the tissues analyzed at the 120 h time point, suggesting that all radioactivity was eliminated by 120 h.
- Details on excretion:
- Excretion in Urine and Feces.
Following a single admin- istration of [35S]MSM, the majority of the radioactivity (85.8%) was excreted in the urine (Table 4). Only a relatively minor amount of the radioactive dose (3.03%) was excreted in the feces. The majority of the radioactivity (58.7%) was excreted within the first 24 h, with 79.0% excreted by 48 h on the basis of radioactivity in urine and feces. Less than 1% of the radioactivity was found in the cage wash (Table 4).
Toxicokinetic parametersopen allclose all
- Toxicokinetic parameters:
- Cmax: 622 ± 37 µg equiv/mL
- Toxicokinetic parameters:
- Tmax: 2.1 ± 1.2 h
- Toxicokinetic parameters:
- other: AUC(0-48): 14052 ± 835 h µg equiv/mL
- Toxicokinetic parameters:
- other: AUC0-inf: 15124 h µg equiv/mL
- Toxicokinetic parameters:
- other: kel: 0.0575 ± 0.0069 1/h
- Toxicokinetic parameters:
- half-life 1st: 12.2 ± 1.4 h
Metabolite characterisation studies
- Metabolites identified:
- no
Any other information on results incl. tables
Table 3.Tissue Concentrations of Radioactivity and Tissue/Blood Ratios following [35S]MSM Administration to Rats
|
|
concentrationa(µg equiv/g) |
|
tissue/blood ratio |
|
tissue |
N |
48 h |
120 h |
48 h |
120 h |
bloodb |
3 |
63.7 ± 12.3 |
N/A |
N/A |
N/A |
liver |
3 |
54.7 ±11.4 |
BLQ |
0.856 |
N/A |
heart |
3 |
59.4 ±11.7 |
BLQ |
0.932 |
N/A |
kidney |
3 |
71.1 ±15.7 |
BLQ |
1.11 |
N/A |
spleen |
3 |
58.2 ±14.4 |
BLQ |
0.909 |
N/A |
testes |
3 |
69.4 ±16.2 |
BLQ |
1.08 |
N/A |
brain |
3 |
58.7 ±11.8 |
BLQ |
0.921 |
N/A |
eye |
3 |
66.7 ±12.9 |
BLQ |
1.05 |
N/A |
skin |
3 |
51.8 ±13.7 |
BLQ |
0.807 |
N/A |
bone |
3 |
35.2 ±0.9 |
BLQ |
0.563 |
N/A |
aValues are expressed as means ±SD. BLQ, below the limit of quantification; N, number; N/A, not applicable.bThis mean blood concentration uses only the same three animals utilized for tissue analysis.
Table 4.Mean Individual and Cumulative Urine, Feces, and Urine +Feces Percent of [35S]MSM Dose Recovered in Ratsa
|
|
urine (% of dose) |
feces (% of dose) |
urine + feces (% of dose) |
|||
time (h) |
N |
individual |
cumulative |
individual |
cumulative |
Individual |
cumulative |
-24 to 0 |
3 |
BLQ |
BLQ |
BLQ |
BLQ |
BLQ |
BLQ |
0-24 |
3 |
57.1 ±6.2 |
57.1 ±6.2 |
1.6 ±0.5 |
1.6 ±0.5 |
58.7 ±6.7 |
58.7 ±6.7 |
24-48 |
3 |
19.2 ±3.9 |
76.3 ±3.8 |
1.1 ±0.4 |
2.7 ±0.4 |
20.3 ±4.4 |
79.0 ±4.1 |
48-72 |
3 |
4.3 ±1.3 |
80.7 ±2.6 |
0.2 ±0.0 |
2.9 ±0.3 |
4.5 ±1.3 |
83.5 ±2.8 |
72-96 |
3 |
1.2 ±0.3 |
81.8 ±2.2 |
0.1 ±0.0 |
3.0 ±0.3 |
1.3 ±0.3 |
84.7 ±2.5 |
96-120 |
3 |
0.3 ±0.1 |
82.1 ±2.2 |
0.0 ±0.0 |
3.0 ±0.3 |
0.44 ±0.1 |
85.1 ±2.4 |
cage wash |
2 |
0.2 ±0.0 |
82.2 ±2.3 |
N/A |
N/A |
0.2 ±0.0 |
85.2 ±2.5 |
cage contents |
3 |
3.6 ±3.0 |
85.8 ±4.8 |
N/A |
N/A |
3.6 ±3.0 |
88.9 ±5.1 |
total |
|
|
85.8 ±4.8 |
|
3.0 ±0.3 |
|
88.9 ±5.1 |
aValues are expressed as means ±SD; BLQ, below the limit of quantification; N, number; N/A, not applicable.
Applicant's summary and conclusion
- Conclusions:
- Interpretation of results (migrated information): no bioaccumulation potential based on study results
MSM is rapidly absorbed, well distributed throughout the body, and quickly eliminated primarily through the urine. No evidence of accumulation in specific tissues was noted. - Executive summary:
The objective of this study was to evaluate the pharmacokinetic profile and distribution of radiolabeled Methylsulfonylmethane (MSM) in rats. Male Sprague-Dawley rats were administered a single oral dose of [35S]MSM (500 mg/kg), and blood levels of radioactivity were determined at different time points for up to 48 h. Tissue levels of radioactivity at 48 and 120 h and urine and fecal radioactivity levels were measured at different time points for up to 120 h following [35S]MSM administration to rats. Oral [35S]MSM was rapidly and efficiently absorbed with a mean tmax of 2.1 h, Cmax of 622 microg equiv/mL, and AUC0-inf of 15124 h.microg equiv/mL. The t1/2 was 12.2 h. Soft tissue distribution of radioactivity indicated a fairly homogeneous distribution throughout the body with relatively lower concentrations in skin and bone. Approximately 85.8% of the dose was recovered in the urine after 120 h, whereas only 3% was found in the feces. No quantifiable levels of radioactivity were found in any tissues after 120 h, indicating complete elimination of [35S]MSM. The results of this study suggest that [35S]MSM is rapidly absorbed, well distributed, and completely excreted from the body.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
